169 related articles for article (PubMed ID: 25694122)
1. Steps and Routes of HCV Infection: The Great Promise of New Anti-Viral Targets.
Crema A; Ponzetto A; Clementi M; Carloni G
Curr Drug Targets; 2015; 16(7):757-70. PubMed ID: 25694122
[TBL] [Abstract][Full Text] [Related]
2. HCV infection by cell-to-cell transmission: choice or necessity?
Carloni G; Crema A; Valli MB; Ponzetto A; Clementi M
Curr Mol Med; 2012 Jan; 12(1):83-95. PubMed ID: 22082483
[TBL] [Abstract][Full Text] [Related]
3. Hepatitis C virus entry into hepatocytes: molecular mechanisms and targets for antiviral therapies.
Zeisel MB; Fofana I; Fafi-Kremer S; Baumert TF
J Hepatol; 2011 Mar; 54(3):566-76. PubMed ID: 21146244
[TBL] [Abstract][Full Text] [Related]
4. Saikosaponin b2 is a naturally occurring terpenoid that efficiently inhibits hepatitis C virus entry.
Lin LT; Chung CY; Hsu WC; Chang SP; Hung TC; Shields J; Russell RS; Lin CC; Li CF; Yen MH; Tyrrell DL; Lin CC; Richardson CD
J Hepatol; 2015 Mar; 62(3):541-8. PubMed ID: 25450204
[TBL] [Abstract][Full Text] [Related]
5. The mechanism of HCV entry into host cells.
Douam F; Lavillette D; Cosset FL
Prog Mol Biol Transl Sci; 2015; 129():63-107. PubMed ID: 25595801
[TBL] [Abstract][Full Text] [Related]
6. New insights into HCV replication: potential antiviral targets.
Rice CM
Top Antivir Med; 2011; 19(3):117-20. PubMed ID: 21946389
[TBL] [Abstract][Full Text] [Related]
7. The history of hepatitis C virus (HCV): Basic research reveals unique features in phylogeny, evolution and the viral life cycle with new perspectives for epidemic control.
Bukh J
J Hepatol; 2016 Oct; 65(1 Suppl):S2-S21. PubMed ID: 27641985
[TBL] [Abstract][Full Text] [Related]
8. [Research on hepatitis C virus entry inhibitor].
Zeng Wenting ; Lu X; Wang J; Jin X; Zhu J
Bing Du Xue Bao; 2015 Jan; 31(1):97-105. PubMed ID: 25997338
[TBL] [Abstract][Full Text] [Related]
9. Virus-host interactions in hepatitis C virus infection: implications for molecular pathogenesis and antiviral strategies.
Georgel P; Schuster C; Zeisel MB; Stoll-Keller F; Berg T; Bahram S; Baumert TF
Trends Mol Med; 2010 Jun; 16(6):277-86. PubMed ID: 20537953
[TBL] [Abstract][Full Text] [Related]
10. Recent advances in our understanding of receptor binding, viral fusion and cell entry of hepatitis C virus: new targets for the design of antiviral agents.
Poumbourios P; Drummer HE
Antivir Chem Chemother; 2007; 18(4):169-89. PubMed ID: 17907376
[TBL] [Abstract][Full Text] [Related]
11. Incorporation of primary patient-derived glycoproteins into authentic infectious hepatitis C virus particles.
Doerrbecker J; Friesland M; Riebesehl N; Ginkel C; Behrendt P; Brown RJ; Ciesek S; Wedemeyer H; Sarrazin C; Kaderali L; Pietschmann T; Steinmann E
Hepatology; 2014 Aug; 60(2):508-20. PubMed ID: 24771613
[TBL] [Abstract][Full Text] [Related]
12. Hepatitis C virus entry: role of host and viral factors.
Samreen B; Khaliq S; Ashfaq UA; Khan M; Afzal N; Shahzad MA; Riaz S; Jahan S
Infect Genet Evol; 2012 Dec; 12(8):1699-709. PubMed ID: 22878095
[TBL] [Abstract][Full Text] [Related]
13. Hepatitis C virus entry: molecular mechanisms and targets for antiviral therapy.
Zeisel MB; Barth H; Schuster C; Baumert TF
Front Biosci (Landmark Ed); 2009 Jan; 14(9):3274-85. PubMed ID: 19273272
[TBL] [Abstract][Full Text] [Related]
14. Mechanism of cell infection with hepatitis C virus (HCV)--a new paradigm in virus-cell interaction.
Budkowska A
Pol J Microbiol; 2009; 58(2):93-8. PubMed ID: 19824391
[TBL] [Abstract][Full Text] [Related]
15. Hepatitis C virus envelope glycoprotein signatures are associated with treatment failure and modulation of viral entry and neutralization.
Schvoerer E; Moenne-Loccoz R; Murray JM; Velay A; Turek M; Fofana I; Fafi-Kremer S; Erba AC; Habersetzer F; Doffoël M; Gut JP; Donlin MJ; Tavis JE; Zeisel MB; Stoll-Keller F; Baumert TF
J Infect Dis; 2013 Apr; 207(8):1306-15. PubMed ID: 23335805
[TBL] [Abstract][Full Text] [Related]
16. (4R,6S)-2-Dihydromenisdaurilide is a Butenolide that Efficiently Inhibits Hepatitis C Virus Entry.
Chung CY; Liu CH; Wang GH; Jassey A; Li CL; Chen L; Yen MH; Lin CC; Lin LT
Sci Rep; 2016 Jul; 6():29969. PubMed ID: 27426693
[TBL] [Abstract][Full Text] [Related]
17. Hepatitis C virus entry.
Zeisel MB; Felmlee DJ; Baumert TF
Curr Top Microbiol Immunol; 2013; 369():87-112. PubMed ID: 23463198
[TBL] [Abstract][Full Text] [Related]
18. Monoclonal Antibodies against Occludin Completely Prevented Hepatitis C Virus Infection in a Mouse Model.
Shimizu Y; Shirasago Y; Kondoh M; Suzuki T; Wakita T; Hanada K; Yagi K; Fukasawa M
J Virol; 2018 Apr; 92(8):. PubMed ID: 29437969
[TBL] [Abstract][Full Text] [Related]
19. Mice Expressing Minimally Humanized CD81 and Occludin Genes Support Hepatitis C Virus Uptake In Vivo.
Ding Q; von Schaewen M; Hrebikova G; Heller B; Sandmann L; Plaas M; Ploss A
J Virol; 2017 Feb; 91(4):. PubMed ID: 27928007
[TBL] [Abstract][Full Text] [Related]
20. Hepatitis C virus depends on E-cadherin as an entry factor and regulates its expression in epithelial-to-mesenchymal transition.
Li Q; Sodroski C; Lowey B; Schweitzer CJ; Cha H; Zhang F; Liang TJ
Proc Natl Acad Sci U S A; 2016 Jul; 113(27):7620-5. PubMed ID: 27298373
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
